The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib

Journal of Hematology and Oncology

Volumn 2, Issue , 2009, Pages

  Masiello, David ^a   Gorospe, Gerry ^a   Yang, Allen S ^a  

^a LAC USC MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID DERIVATIVE; DASATINIB; DIURETIC AGENT; IMATINIB; NILOTINIB; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOPENIA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLUID RETENTION; HUMAN; LIVER TOXICITY; OXYGEN THERAPY; PATIENT EDUCATION; PATIENT MONITORING; PERIPHERAL EDEMA; PLEURA EFFUSION; RECOMMENDED DRUG DOSE; RISK FACTOR; SIDE EFFECT; THORACOCENTESIS; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; ALGORITHM; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; EVALUATION; INCIDENCE; METABOLIC DISORDER; REVIEW;

ALGORITHMS; HUMANS; INCIDENCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PLEURAL EFFUSION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; THIAZOLES; WATER-ELECTROLYTE IMBALANCE;

EID: 72449169564     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-2-46     Document Type: Article

References (32)

1. Surveillance Epidemiology and End Results web site: Finding Cancer Statistics: Cancer Stat Fact Sheets: Chronic Myeloid Leukemia. National Cancer Institute. US National Institutes of Health, National Cancer Institute http://seer.cancer.gov/statfacts/html/cmyl.html Accessed August 20, 2008
2. Chronic myelogenous leukemia V.2.2009. NCCN Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network (NCCN), http://www.nccn.org/ professionals/physician-gls/PDF/cml.pdf Accessed September 20, 2009
3. Chronic myeloid leukemia. CL Sawyers, N Engl J Med 1999 340 17 1330 1340 10.1056/NEJM199904293401706 10219069
4. Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. CR Bartram A de Klein A Hagemeijer T van Agthoven A Geurts van Kessel D Bootsma G Grosveld MA Ferguson-Smith T Davies M Stone N Heisterkamp JR Stephenson J Groffen, Nature 1983 306 5940 277 280 10.1038/306277a0 6580527
5. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. J Groffen JR Stephenson N Heisterkamp A de Klein CR Bartram Grosveld, Cell 1984 36 1 93 99 10.1016/0092-8674(84)90077-1 6319012
6. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. TG Lugo AM Pendergast AJ Muller ON Witte, Science 1990 247 4946 1079 1082 10.1126/science.2408149 2408149
7. The biology of chronic myelogenous leukemia: implications for imatinib therapy. RH Alvarez H Kantarjian JE Cortes, Semin Hematol 2007 44 1 Suppl 1 4 S14 10.1053/j.seminhematol.2006.12.007 17292736
8. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. HM Kantarjian M Talpaz F Giles S O'Brien J Cortes, Ann Intern Med 2006 145 12 913 923 17179059 (Pubitemid 351639967)
9. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. BJ Druker F Guilhot SG O'Brien I Gathmann H Kantarjian N Gattermann MW Deininger RT Silver JM Goldman RM Stone F Cervantes A Hochhaus BL Powell JL Gabrilove P Rousselot J Reiffers JJ Cornelissen T Hughes H Agis T Fischer G Verhoef J Shepherd G Saglio A Gratwohl JL Nielsen JP Radich B Simonsson K Taylor M Baccarani C So L Letvak RA Larson IRIS Investigators, N Engl J Med 2006 355 23 2408 2417 10.1056/NEJMoa062867 17151364 (Pubitemid 44903745)
10. Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. T Hughes S Branford, Blood Rev 2006 20 1 29 41 10.1016/j.blre.2005.01.008 16426942
11. International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP) treated with imatinib (IM) [abstract 186]. SG O'Brien F Guilhot JM Goldman, Blood 2008 112 11
12. Imatinib use in chronic phase CML in clinical practice: the UNIC study [abstract 7077]. JL Steegman M Michallet E Morra D Marin GJ Ossenkoppele G Verhoef T Kühr M Björeman M Sterckx K Cerri, J Clin Oncol 2008 26 15s 391s
13. Nilotinib prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corporation 2007 http://www.pharma.us.novartis.com/product/pi/ pdf/tasigna.pdf
14. Dasatinib prescribing information. Princeton, NJ: Bristol-Myers Squibb Company 2009 http://packageinserts.bms.com/pi/pi-sprycel.pdf
15. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. LJ Lombardo FY Lee P Chen D Norris JC Barrish K Behnia S Castaneda LA Cornelius J Das AM Doweyko C Fairchild JT Hunt I Inigo K Johnston A Kamath D Kan H Klei P Marathe S Pang R Peterson S Pitt GL Schieven RJ Schmidt J Tokarski ML Wen J Wityak RM Borzilleri, J Med Chem 2004 47 27 6658 6661 10.1021/jm049486a 15615512
16. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. T O'Hare DK Walters EP Stoffregen T Jia PW Manley J Mestan SW Cowan-Jacob FY Lee MC Heinrich MW Deininger BJ Druker, Cancer Res 2005 65 11 4500 4505 10.1158/0008-5472.CAN- 05-0259 15930265
17. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. T O'Hare CA Eide MW Deininger, Blood 2007 110 7 2242 2249 10.1182/blood-2007-03-066936 17496200
18. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. J Cortes P Rousselot DW Kim E Ritchie N Hamerschlak S Coutre A Hochhaus F Guilhot G Saglio J Apperley O Ottmann N Shah P Erben S Branford P Agarwal A Gollerkeri M Baccarani, Blood 2007 109 8 3207 3213 10.1182/blood-2006-09-046888 17185463 (Pubitemid 46572505)
19. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. F Guilhot J Apperley DW Kim EO Bullorsky M Baccarani GJ Roboz S Amadori CA de Souza JH Lipton A Hochhaus D Heim RA Larson S Branford MC Muller P Agarwal A Gollerkeri M Talpaz, Blood 2007 109 10 4143 4150 10.1182/blood-2006-09-046839 17264298 (Pubitemid 46743375)
20. Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy. A Hochhaus HM Kantarjian M Baccarani JH Lipton JF Apperley BJ Druker T Facon SL Goldberg F Cervantes D Niederwieser RT Silver RM Stone TP Hughes MC Muller R Ezzeddine AM Countouriotis NP Shah, Blood 2007 109 6 2303 2309 10.1182/blood-2006-09-047266 17138817 (Pubitemid 46425867)
21. Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C) [abstract 7009]. MJ Mauro M Baccarani F Cervantes JH Lipton Y Matloub R Sinha RM Stone, J Clin Oncol 2008 26 15s 374s
22. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. NP Shah HM Kantarjian DW Kim D Réa PE Dorlhiac-Llacer JH Milone J Vela-Ojeda RT Silver HJ Khoury A Charbonnier N Khoroshko RL Paquette M Deininger RH Collins I Otero T Hughes E Bleickardt L Strauss S Francis A Hochhaus, J Clin Oncol 2008 26 19 3204 3212 10.1200/JCO.2007.14.9260 18541900
23. Dasatinib lack of cross intolerance to imatinib in patients (pts) with chronic myelogenous leukemia chronic phase (CML-CP) intolerant to imatinib: a retrospective analysis of safety [abstract 7015]. HJ Khoury SL Goldberg M Mauro RM Stone Y Matloub T Chen F Guilhot, J Clin Oncol 2008 26 15s 375s
24. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. H de Lavallade S Punnialingam D Milojkovic M Bua JS Khorashad IH Gabriel A Chaidos E Olavarria JM Goldman JF Apperley D Marin, Br J Haematol 2008 141 5 745 747 10.1111/j.1365-2141.2008.07108.x 18331365
25. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. A Quintas-Cardama H Kantarjian S O'Brien G Borthakur J Bruzzi R Munden J Cortes, J Clin Oncol 2007 25 25 3908 3914 10.1200/JCO.2007.12.0329 17761974
26. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. A Bergeron D Rea V Levy C Picard V Meignin J Tamburini H Bruzzoni-Giovanelli F Calvo A Tazi P Rousselot, Am J Respir Crit Care Med 2007 176 8 814 818 10.1164/rccm.200705-715CR 17600277
27. The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. S Blake TP Hughes G Mayrhofer AB Lyons, Clin Immunol 2008 127 3 330 339 10.1016/j.clim.2008.02.006 18395492
28. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. U Rix O Hantschel G Durnberger LL Remsing Rix M Planyavsky NV Fernbach I Kaupe KL Bennett P Valent J Colinge T Köcher G Superti-Furga, Blood 2007 110 12 4055 4063 10.1182/blood-2007-07-102061 17720881
29. Management of Bcr-Abl-positive leukemias with dasatinib. A Hochhaus, Expert Rev Anticancer Ther 2007 7 11 1529 1536 10.1586/14737140.7.11.1529 18020922
30. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. HM Kantarjian F Giles N Gattermann, et al. Blood 2007 110 3540 3546 10.1182/blood-2007-03-080689 17715389
31. A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinib-resistant or -intolerant patients with Philadelphia-positive chronic myelogenous leukemia in accelerated phase. P Le Coutre R Larson H Kantarjian, et al. Haematologica 2007 92 suppl 1 557
32. Nilotinib monotherapy in patients with imatinib-resistant or -intolerant Ph+ chronic myelogenous leukemia (CML) in blast crisis or relapsed/refractory Ph+ acute lymphoblastic leukemia. O Ottmann R Larson H Kantarjian, et al. Haematologica 2007 92 suppl 1 556